This National Science Foundation (NSF) Engineering (CFDA 47.041) Project Grant award of $379,730 to the University of North Carolina at Chapel Hill aims to develop a continuous electrochemical sensor for monitoring the concentration of the therapeutic monoclonal antibody bevacizumab in patients. The research will focus on designing anti-idiotype bevacizumab aptamers that incorporate azobenzene to enable reversible, light-sensitive conformational changes for regenerating the binding site. This will address the challenge of discriminating between therapeutic monoclonal antibodies and human IgG in biological fluids for continuous in vivo monitoring. The findings will be integrated into graduate and undergraduate coursework to disseminate the research to a broader audience. The award period runs from December 1, 2024 to November 30, 2027.
Generated 3/25/25, 5:02 AM